Coronavirus infection and immune system: An insight of COVID-19 in cancer patients.
COVID-19
Cancer
Coronavirus
Immunotherapy
Infection
Oncology
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
04
05
2020
revised:
02
07
2020
accepted:
07
07
2020
pubmed:
28
7
2020
medline:
18
9
2020
entrez:
26
7
2020
Statut:
ppublish
Résumé
The novel coronavirus respiratory illness (COVID-19) is a public health emergency of global concern. Patients with cancer are at high risk of infections, due to an overall immunocompromised status. However, this connection is not straightforward for coronavirus (CoV) infection, in which the host immune response is the main driver of tissue damage. We performed a thorough review of data on CoV pathogenesis and morbidity rate in cancer patients, through the analysis of the previous CoV pandemics. Considering the interaction between CoV and the host immune system, cancer patients receiving immunotherapy might be more at risk for an aberrant immune response in case of infection, and might therefore deserve additional precautions. The limited available data do not allow us to provide practical indications for the management of cancer patients in this critical situation. Efforts should be made to prospectively collect data, to identify effective interventions to guide treatment decision.
Identifiants
pubmed: 32711241
pii: S1040-8428(20)30195-5
doi: 10.1016/j.critrevonc.2020.103059
pmc: PMC7347348
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103059Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Am Soc Clin Oncol Educ Book. 2018 May 23;38:400-414
pubmed: 30231397
Cancer Discov. 2020 Aug;10(8):1121-1128
pubmed: 32398243
N Engl J Med. 2019 Apr 25;380(17):1667-1668
pubmed: 30969502
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Molecules. 2019 Sep 04;24(18):
pubmed: 31487832
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Viruses. 2019 Oct 18;11(10):
pubmed: 31635238
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
J Infect Dis. 2016 Mar 15;213(6):877-9
pubmed: 26203059
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
JCO Glob Oncol. 2020 Mar;6:471-475
pubmed: 32196389
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
Eur Surg Res. 2012;48(4):180-6
pubmed: 22653168
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Ann Oncol. 2020 Jul;31(7):832-834
pubmed: 32278879
Curr Oncol Rep. 2016 Sep;18(9):56
pubmed: 27475805
Asia Pac J Public Health. 2010 Jul;22(3 Suppl):132S-136S
pubmed: 20566545
Cytokine. 2018 Apr;104:8-13
pubmed: 29414327
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
J Oncol. 2019 Sep 24;2019:2592419
pubmed: 31662750
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Semin Immunopathol. 2016 Jul;38(4):471-82
pubmed: 26965109
Ann Oncol. 2020 May;31(5):553-555
pubmed: 32201224
Lancet Oncol. 2020 May;21(5):619-621
pubmed: 32220659
JAMA Oncol. 2020 May 1;6(5):631-632
pubmed: 32236504
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Ann Intern Med. 2020 Jun 2;172(11):756-758
pubmed: 32219410
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
Eur J Cancer. 2020 Aug;135:47-50
pubmed: 32534244
Ann Rheum Dis. 2017 Dec;76(12):2061-2064
pubmed: 28830882
J Immunother. 2012 Feb-Mar;35(2):169-78
pubmed: 22306905
J Pathol. 2015 Jan;235(2):185-95
pubmed: 25270030
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet Infect Dis. 2018 Aug;18(8):e217-e227
pubmed: 29680581
Eur J Cancer. 2020 Jun;132:17-23
pubmed: 32311643
J Cancer Res Clin Oncol. 2019 Feb;145(2):511-521
pubmed: 30539281
BMJ. 2020 Mar 25;368:m1174
pubmed: 32213482
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28
pubmed: 30678413
Hum Vaccin Immunother. 2015;11(11):2606-14
pubmed: 26110220
J Natl Compr Canc Netw. 2020 Jan;18(1):12-22
pubmed: 31910384
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2019 Jul 18;10:1690
pubmed: 31379875
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
Curr Opin Infect Dis. 2012 Aug;25(4):423-30
pubmed: 22766648
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
ESMO Open. 2020 Mar;5(2):
pubmed: 32229501